Evidence map›Paper›PMID 42335443›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2026

Specific HLA-DRB1 Alleles Associate With Anti-Caspr1 and Anti-CNTN1 Autoantibodies in Autoimmune Nodopathies.

Cinta Lleixà, Elba Pascual-Goñi, Lorena Martín-Aguilar, Marta Caballero-Ávila, Roger Collet-Vidiella, Clara Tejada-Illa, Paula Llarch, Eduard Gallardo, Gemma Boera-Carnicero, Verónica Calahorro and 31 more

Abstract read
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors.

Cinta LleixàNeuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, IR Sant Pau, Barcelona, Spain.ORCID 0000-0002-9971-0584
Elba Pascual-GoñiNeuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, IR Sant Pau, Barcelona, Spain.ORCID 0000-0001-7336-4305
Lorena Martín-AguilarNeuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, IR Sant Pau, Barcelona, Spain.ORCID 0000-0002-1553-2224
Marta Caballero-ÁvilaNeuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, IR Sant Pau, Barcelona, Spain.ORCID 0000-0001-9850-8504
Roger Collet-VidiellaNeuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, IR Sant Pau, Barcelona, Spain.ORCID 0000-0003-1668-1018
Clara Tejada-IllaNeuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, IR Sant Pau, Barcelona, Spain.ORCID 0009-0008-2856-7179
Paula LlarchNeuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, IR Sant Pau, Barcelona, Spain.ORCID 0009-0008-0098-7155
Eduard GallardoNeuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, IR Sant Pau, Barcelona, Spain.ORCID 0000-0002-3942-3436
Gemma Boera-CarniceroDepartment of Immunology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Verónica CalahorroDepartment of Immunology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.ORCID 0009-0000-4754-7837
Ilaria CallegariDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, United Kingdom.ORCID 0000-0003-3361-3084
Andrea CorteseDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, United Kingdom.ORCID 0000-0002-2208-5311
Emilien DelmontReferral Centre for Neuromuscular Diseases and ALS, La Timone Hospital, Marseille, France.ORCID 0000-0002-5591-2774
Jerome DevauxInstitut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM, France.ORCID 0000-0001-6383-4334
Claudia C GiannottaNeuromuscular and Neuroimmunology Unit, IRCCS Humanitas Research Hospital, Milan University, Italy.
Eduardo Nobile-OrazioNeuromuscular and Neuroimmunology Unit, IRCCS Humanitas Research Hospital, Milan University, Italy.ORCID 0000-0003-2624-8138
Romana HöftbergerDivision of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Austria.ORCID 0000-0002-5769-1100
Johann SellnerDepartment of Neurology, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria; Affiliated with Karl Landsteiner University of Health Sciences, Krems, Austria.ORCID 0000-0001-8749-5533
Sarah Andrée Annie J HerdewynDepartment of Neurology and Neuromuscular Reference Center, Ghent University Hospital, Belgium.
Carvajal AlejandraDepartment of Neurology, Hospital Virgen de las Nieves, Granada, Spain.
Laura TornéDepartment of Neurology, Hospital Universitario de Navarra, Pamplona, Spain.ORCID 0000-0002-5672-0280
Ivonne JericóDepartment of Neurology, Hospital Universitario de Navarra, Pamplona, Spain.ORCID 0000-0003-4262-6370
Simon RinaldiNuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom.ORCID 0000-0003-2039-3457
Claudia SommerDepartment of Neurology, University Hospital Würzburg, Germany.ORCID 0000-0002-7064-5002
Kathrin DopplerDepartment of Neurology, University Hospital Würzburg, Germany.ORCID 0000-0003-2883-0009
Thais ArmangueNeuroimmunology Program, IDIBAPS-Hospital Clínic de Barcelona, Spain.ORCID 0000-0001-6192-6171
Maarten J TitulaerDepartment of Neurology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-1033-3840
Bart C JacobsDepartment of Neurology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-8985-2458
Ruth HuizingaDepartment of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-9563-4860
Julia V WanschitzDepartment of Neurology, Medical University of Innsbruck, Austria.ORCID 0000-0002-0207-9977
Nicolau Ortiz CastellonDepartment of Neurology, Hospital Universitari Sant Joan, Reus, Spain.
Davide SparasciDepartment of Neurology, Neurocenter of Southern Switzerland EOC.ORCID 0000-0002-6190-1633
Paolo RipellinoDepartment of Neurology, Neurocenter of Southern Switzerland EOC.ORCID 0000-0002-8662-9656
Helena Pérez-PérezDepartment of Neurology, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain.
Alejandro HorgaDepartment of Neurology, Hospital Universitario Clínico San Carlos, Madrid, Spain.ORCID 0000-0002-2120-2213
Alicia Alonso-JiménezNeuromuscular Reference Centre, Department of Neurology, Antwerp University Hospital, Belgium; and.
Jonathan De WinterNeuromuscular Reference Centre, Department of Neurology, Antwerp University Hospital, Belgium; and.ORCID 0000-0002-0166-6758
Amaia JaureguiDepartment of Neurology, Hospital Universitario de Cruces, Barakaldo, Spain.
Oscar de la Calle-MartinDepartment of Immunology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.ORCID 0000-0001-9717-053X
Laura Martinez-MartinezDepartment of Immunology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.ORCID 0000-0003-0126-158X
Luis QuerolNeuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, IR Sant Pau, Barcelona, Spain.ORCID 0000-0002-4289-8264

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesThis study describes the human leukocyte antigen (HLA) Class II allele frequencies in patients with anti-CNTN1+ and anti-Caspr1+ autoimmune nodopathy (AN).

methodsForty-four AN patients and 50 seronegative CIDP patients from 19 different European hospitals were included in the study. Thirty AN patients had anti-contactin 1 (CNTN1) antibodies, 11 anti-contactin-associated protein 1 (Caspr1) antibodies, and 3 had antibodies against both proteins. HLA-DRB1 was genotyped at the 4-digit allele levels, and the percentage of individuals carrying each allele was compared with that of the general population, obtained from the

resultsHLA-DRB1*11 alleles appeared in higher proportions in anti-CNTN1+ patients than in seronegative CIDP patients and in the general population (46.7% vs 18% vs 28.4%), with an odds ratio of 3.99 (CI = 1.44 to 11.03, DISCUSSION: HLA-DRB1*11 alleles are associated with the detection of anti-CNTN1 antibodies in AN patients, and HLA-DRB1*03:01 alleles associate with anti-Caspr1 antibodies. In addition, our study suggests that antiparanodal antibodies targeting both Caspr1 and CNTN1 are present in a small number of patients with AN. These data reinforce the idea that these patients represent specific subsets with clinical features and risk factors that differ from seronegative CIDP patients and from other AN patients. However, further studies should address the functional relevance of these associations and their pathophysiologic implications.

Indexed as

AutoantibodiesAutoimmune Diseases of the Nervous SystemContactin 1HLA-DRB1 ChainsAdultAgedFemaleGene FrequencyHumansMaleMiddle AgedAutoantibodiesCNTN1 protein, humanContactin 1HLA-DRB1 Chains

Identifiers

PMID42335443
PMCPMC13293632

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.